v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash $ 142 $ 190
Accounts receivable 109 24
Employee advance 5
Net investment in leases, short term 13 103
Prepaid expenses and vendor deposits 80 206
Total current assets 344 528
Property and equipment, net 85 509
Right-to-use assets, net 96 412
Other assets:    
Net investment in leases, long term 4 17
Patents, net 269 288
Other assets 44 44
Total assets 842 1,798
Current liabilities:    
Accounts payable and accrued expenses, including $19 and $30 to related parties as of December 31, 2024 and 2023, respectively 2,052 4,116
Customer deposits 16
Dividends payable 110 101
Lease liability, short term 102 349
Total current liabilities 2,264 4,582
Long term liabilities:    
Lease liability, long term 103
Total long term liabilities 103
Total liabilities 2,264 4,685
Commitments and contingencies (Note 12)
Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of December 31, 2024 and 2023 105 105
Deficit    
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. 105 shares of Series C outstanding as of December 31, 2024 and 2023 (see above)
Common stock, $0.001 par value, authorized 200,000,000 shares, 17,239,096 and 9,040,043 issued and outstanding as of December 31, 2024 and 2023, respectively 17 9
Additional paid in capital 253,784 241,988
Accumulated deficit (255,345) (245,015)
Total stockholders’ deficit attributable to BioSig Technologies, Inc. (1,544) (3,018)
Non controlling interest 17 26
Total deficit (1,527) (2,992)
Total liabilities and deficit $ 842 $ 1,798

Source

PDF HTML
10-K Filing
ZIP XLS
XBRL